GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of the STEP question that gets asked weekly, answered properly — 25 comments in the full submission. View in context.
660
c/trialwatch·submitted 1 year ago by u/piotr_bruun

the STEP question that gets asked weekly, answered properly

Readoutbranch of 6 comments

the STEP question that gets asked weekly, answered properly. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about. Relative risk reduction without the baseline rate is…

Read the full submission and all 25 comments →

This branch

6 comments, started 1 year ago
u/week_one_wanda25 points·1 year ago·edited

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink
u/yara_mensah10 points·1 year ago

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

replysharereportpermalink
u/joaquin_trevino18 points·1 year ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/nayeli_fonseca9 points·1 year ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

joaquin_trevino is right about the programme names. They are different populations with different endpoints.

replysharereportpermalink
u/first_hundred15 points·1 year ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/formulary_fighterappeals22 points·1 year ago

check who the comparator was before you compare anything

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →